Angela Mastronuzzi/LinkedIn
Apr 11, 2025, 22:26
Angela Mastronuzzi: 131I-mIBG therapy in relapsed/refractory neuroblastoma – an old bridge to the future
Angela Mastronuzzi, Head of Neuro-Oncology Unit at Bambino Gesù Children’s Hospital and President of AIEOP, shared a post on LinkedIn:
” ’31I-mIBG therapy in relapsed/refractory neuroblastoma: an old bridge to the future’ – just published with ESMO – European Society for Medical Oncology
31I-mIBG therapy plus melphalan is confirmed to be effective to reduce/control tumour burden. Further studies are needed to clarify the role and timing of this treatment and to integrate its role in the strategy of CAR-T cells.”
“131I-mIBG therapy in relapsed/refractory neuroblastoma: an old bridge to the future”
Authors: M.A. De Ioris et al.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Apr 15, 2025, 11:00
Apr 15, 2025, 10:23
Apr 15, 2025, 10:22
Apr 15, 2025, 10:17
Apr 15, 2025, 10:09
Apr 15, 2025, 10:04
Apr 15, 2025, 09:54
Apr 15, 2025, 09:48
Apr 15, 2025, 09:45
Apr 15, 2025, 09:37